Q-omics provides the consensus-scored GRAMD4P8 profile across patient tissues and cancer cell-line models. GRAMD4P8 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, GRAMD4P8 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, GRAMD4P8 RNA expression shows 13,703 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, KIRC, and THYM as cancer lineages where GRAMD4P8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRAMD4P8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRAMD4P8 survival associations across molecular data types. GRAMD4P8 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRAMD4P8 RNA expression–survival associations across cancer types. High GRAMD4P8 expression shows unfavorable associations in READ and KIRP, but favorable associations in BRCA, HNSC, LAML and ACC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for GRAMD4P8 RNA expression.
This table summarizes GRAMD4P8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GRAMD4P8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRAMD4P8 shows higher tumor expression in KIRC, BRCA, KIRP, HNSC, LIHC and LUAD. The KIRC box plot shows higher GRAMD4P8 RNA expression in tumor versus normal tissue (log2 FC = +0.099, t-test p < 0.001).
This table shows molecular features associated with GRAMD4P8 in patient tissues and cancer cell lines. In patient samples, GRAMD4P8 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
